Skip to main content
Erschienen in: AIDS and Behavior 8/2021

27.02.2021 | Original Paper

Predictors of Event-Driven Regimen Choice in Current PrEP Users and Sexual Behavior Characteristics of MSM Receiving Sexual Health Services in New York City

verfasst von: Pedro B. Carneiro, Christopher Rincon, Sarit Golub

Erschienen in: AIDS and Behavior | Ausgabe 8/2021

Einloggen, um Zugang zu erhalten

Abstract

While daily PrEP is undeniably effective, broad-based adoption remains low. Non-daily PrEP modalities, like event-driven PrEP (ED PrEP), offer an efficient way to deliver PrEP’s protection to priority populations. We carried out an at-home survey with patients receiving sexual health services in a LGBTQ-clinic in New York (n = 147). Participants answered questions on ED PrEP awareness and preferences, sexual behavior, and sexual preparatory practices. Only 50% of our sample were aware of ED PrEP, about 30% met eligibility for ED PrEP, and 35% chose ED PrEP as a good HIV prevention option for them. In a robust Poisson model (n = 128), endorsement of ED PrEP as a good prevention choice was significantly more common in participants who were uninsured, preferred taking PrEP only when needed, and those who had concerns about side-effects. Furthermore, participants reported many sexual behaviors patterns and preparatory practices compatible with use of ED PrEP.
Literatur
1.
Zurück zum Zitat CDC. Estimated HIV incidence and prevalence in the United States, 2014–2018. HIV Surveillance Supplemental Report. Atlanta: CDC; 2020. CDC. Estimated HIV incidence and prevalence in the United States, 2014–2018. HIV Surveillance Supplemental Report. Atlanta: CDC; 2020.
2.
Zurück zum Zitat Grant RM, Anderson PL, Mcmahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9.CrossRef Grant RM, Anderson PL, Mcmahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9.CrossRef
3.
Zurück zum Zitat Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, et al. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med. 2016;176(1):75.CrossRef Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, et al. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med. 2016;176(1):75.CrossRef
4.
Zurück zum Zitat Mccormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60.CrossRef Mccormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60.CrossRef
5.
Zurück zum Zitat CDC. Preexposure prophylaxis for the prevention of HIV infection in the United States—2017 update: a clinical practice guideline. Atlanta: CDC website; 2018. CDC. Preexposure prophylaxis for the prevention of HIV infection in the United States—2017 update: a clinical practice guideline. Atlanta: CDC website; 2018.
6.
Zurück zum Zitat Smith D, Van Handel M, Grey J. By race/ethnicity, blacks have highest number needing PrEP in the United States, 2015. Paper presented at the Conference on retroviruses and Opportunistic Infections 2018. Smith D, Van Handel M, Grey J. By race/ethnicity, blacks have highest number needing PrEP in the United States, 2015. Paper presented at the Conference on retroviruses and Opportunistic Infections 2018.
7.
Zurück zum Zitat AVAC. United States—PrEPWatch [Internet]. 2018. AVAC. United States—PrEPWatch [Internet]. 2018.
8.
Zurück zum Zitat Elion RA, Kabiri M, Mayer KH, Wohl DA, Cohen J, Beaubrun AC, et al. Estimated impact of targeted pre-exposure prophylaxis: strategies for men who have sex with men in the United States. Int J Environ Res Public Health. 2019;16(9):1592.CrossRef Elion RA, Kabiri M, Mayer KH, Wohl DA, Cohen J, Beaubrun AC, et al. Estimated impact of targeted pre-exposure prophylaxis: strategies for men who have sex with men in the United States. Int J Environ Res Public Health. 2019;16(9):1592.CrossRef
9.
Zurück zum Zitat Patel R, Singh S, Farag C, et al. Out-of-pocket costs impede PrEP use among young MSM in the private healthcare system. Presented at Conference on Retroviruses and Opportunistic Infections 2018. Patel R, Singh S, Farag C, et al. Out-of-pocket costs impede PrEP use among young MSM in the private healthcare system. Presented at Conference on Retroviruses and Opportunistic Infections 2018.
10.
Zurück zum Zitat Golub SA. PrEP stigma: implicit and explicit drivers of disparity. Curr HIV/AIDS Rep. 2018;15(2):190–7.CrossRef Golub SA. PrEP stigma: implicit and explicit drivers of disparity. Curr HIV/AIDS Rep. 2018;15(2):190–7.CrossRef
11.
Zurück zum Zitat Touger R, Wood BR. A review of telehealth innovations for HIV pre-exposure prophylaxis (PrEP). Curr HIV/AIDS Rep. 2019;16(1):113–9.CrossRef Touger R, Wood BR. A review of telehealth innovations for HIV pre-exposure prophylaxis (PrEP). Curr HIV/AIDS Rep. 2019;16(1):113–9.CrossRef
12.
Zurück zum Zitat Rendina HJ, Whitfield THF, Grov C, Starks TJ, Parsons JT. Distinguishing hypothetical willingness from behavioral intentions to initiate HIV pre-exposure prophylaxis (PrEP): findings from a large cohort of gay and bisexual men in the U.S. Social Sci Med. 2017;172:115–23.CrossRef Rendina HJ, Whitfield THF, Grov C, Starks TJ, Parsons JT. Distinguishing hypothetical willingness from behavioral intentions to initiate HIV pre-exposure prophylaxis (PrEP): findings from a large cohort of gay and bisexual men in the U.S. Social Sci Med. 2017;172:115–23.CrossRef
13.
Zurück zum Zitat Ellison J, Van Den Berg JJ, Montgomery MC, Tao J, Pashankar R, Mimiaga MJ, et al. Next-generation HIV pre-exposure prophylaxis preferences among men who have sex with men taking daily oral pre-exposure prophylaxis. AIDS Patient Care STDs. 2019;33(11):482–91.CrossRef Ellison J, Van Den Berg JJ, Montgomery MC, Tao J, Pashankar R, Mimiaga MJ, et al. Next-generation HIV pre-exposure prophylaxis preferences among men who have sex with men taking daily oral pre-exposure prophylaxis. AIDS Patient Care STDs. 2019;33(11):482–91.CrossRef
14.
Zurück zum Zitat Holt M, Murphy DA. Individual versus community-level risk compensation following preexposure prophylaxis of HIV. Am J Public Health. 2017;107(10):1568–71.CrossRef Holt M, Murphy DA. Individual versus community-level risk compensation following preexposure prophylaxis of HIV. Am J Public Health. 2017;107(10):1568–71.CrossRef
15.
Zurück zum Zitat Kibengo FM, Ruzagira E, Katende D, Bwanika AN, Bahemuka U, Haberer JE, et al. Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial. PLoS ONE. 2013;8(9):e74314.CrossRef Kibengo FM, Ruzagira E, Katende D, Bwanika AN, Bahemuka U, Haberer JE, et al. Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial. PLoS ONE. 2013;8(9):e74314.CrossRef
16.
Zurück zum Zitat Molina J-M, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237–46.CrossRef Molina J-M, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237–46.CrossRef
17.
Zurück zum Zitat Molina J-M, Charreau I, Spire B, Cotte L, Chas J, Capitant C, et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017;4(9):e402–10.CrossRef Molina J-M, Charreau I, Spire B, Cotte L, Chas J, Capitant C, et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017;4(9):e402–10.CrossRef
18.
Zurück zum Zitat Grant RM, Mannheimer S, Hughes JP, Hirsch-Moverman Y, Loquere A, Chitwarakorn A, et al. Daily and nondaily oral preexposure prophylaxis in men and transgender women who have sex with men: the human immunodeficiency virus prevention trials network 067/ADAPT study. Clin Infect Dis. 2018;66(11):1712–21.CrossRef Grant RM, Mannheimer S, Hughes JP, Hirsch-Moverman Y, Loquere A, Chitwarakorn A, et al. Daily and nondaily oral preexposure prophylaxis in men and transgender women who have sex with men: the human immunodeficiency virus prevention trials network 067/ADAPT study. Clin Infect Dis. 2018;66(11):1712–21.CrossRef
19.
Zurück zum Zitat Molina J-M, Capitant C, Spire B, Pialoux, G., Chidiac C, et al. On demand PrEP with oral TDF-FTC in MSM: results of the ANRS Ipergay trial. Paper presented at the Conference on retroviruses and opportunistic infections 2015. Molina J-M, Capitant C, Spire B, Pialoux, G., Chidiac C, et al. On demand PrEP with oral TDF-FTC in MSM: results of the ANRS Ipergay trial. Paper presented at the Conference on retroviruses and opportunistic infections 2015.
20.
Zurück zum Zitat Siguier M, Mera R, Pialoux G, Ohayon M, Cotte L, Valin N, et al. First year of pre-exposure prophylaxis implementation in France with daily or on-demand tenofovir disoproxil fumarate/emtricitabine. J Antimicrob Chemother. 2019;74(9):2752–8.CrossRef Siguier M, Mera R, Pialoux G, Ohayon M, Cotte L, Valin N, et al. First year of pre-exposure prophylaxis implementation in France with daily or on-demand tenofovir disoproxil fumarate/emtricitabine. J Antimicrob Chemother. 2019;74(9):2752–8.CrossRef
21.
Zurück zum Zitat Reyniers T, Nöstlinger C, Laga M, De Baetselier I, Crucitti T, Wouters K, et al. Choosing between daily and event-driven pre-exposure prophylaxis: results of a Belgian PrEP demonstration project. J Acquir Immune Defic Syndr. 2018;79(2):186–94.CrossRef Reyniers T, Nöstlinger C, Laga M, De Baetselier I, Crucitti T, Wouters K, et al. Choosing between daily and event-driven pre-exposure prophylaxis: results of a Belgian PrEP demonstration project. J Acquir Immune Defic Syndr. 2018;79(2):186–94.CrossRef
22.
Zurück zum Zitat Zimmermann HM, Eekman SW, Achterbergh RC, Schim Van Der Loeff MF, Prins M, Vries HJ, et al. Motives for choosing, switching and stopping daily or event-driven pre-exposure prophylaxis—a qualitative analysis. J Int AIDS Soc. 2019;22(10):e25389.CrossRef Zimmermann HM, Eekman SW, Achterbergh RC, Schim Van Der Loeff MF, Prins M, Vries HJ, et al. Motives for choosing, switching and stopping daily or event-driven pre-exposure prophylaxis—a qualitative analysis. J Int AIDS Soc. 2019;22(10):e25389.CrossRef
23.
Zurück zum Zitat Vaccher SJ, Gianacas C, Templeton DJ, Poynten IM, Haire BG, Ooi C, et al. Baseline preferences for daily, event-driven, or periodic HIV pre-exposure prophylaxis among gay and bisexual men in the PRELUDE demonstration project. Front Public Health. 2017;5:341.CrossRef Vaccher SJ, Gianacas C, Templeton DJ, Poynten IM, Haire BG, Ooi C, et al. Baseline preferences for daily, event-driven, or periodic HIV pre-exposure prophylaxis among gay and bisexual men in the PRELUDE demonstration project. Front Public Health. 2017;5:341.CrossRef
24.
Zurück zum Zitat Sewell WC, Powell VE, Mayer KH, Ochoa A, Krakower DS, Marcus JL. Nondaily use of HIV preexposure prophylaxis in a large online survey of primarily men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2020;84(2):182–8.CrossRef Sewell WC, Powell VE, Mayer KH, Ochoa A, Krakower DS, Marcus JL. Nondaily use of HIV preexposure prophylaxis in a large online survey of primarily men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2020;84(2):182–8.CrossRef
25.
Zurück zum Zitat Shrestha R, Karki P, Altice FL, Dubov O, Fraenkel L, Huedo-Medina T, et al. Measuring acceptability and preferences for implementation of pre-exposure prophylaxis (PrEP) using conjoint analysis: an application to primary HIV prevention among high risk drug users. AIDS Behav. 2018;22(4):1228–38.CrossRef Shrestha R, Karki P, Altice FL, Dubov O, Fraenkel L, Huedo-Medina T, et al. Measuring acceptability and preferences for implementation of pre-exposure prophylaxis (PrEP) using conjoint analysis: an application to primary HIV prevention among high risk drug users. AIDS Behav. 2018;22(4):1228–38.CrossRef
26.
Zurück zum Zitat Dubov A, Ogunbajo A, Altice FL, Fraenkel L. Optimizing access to PrEP based on MSM preferences: results of a discrete choice experiment. AIDS Care. 2019;31(5):545–53.CrossRef Dubov A, Ogunbajo A, Altice FL, Fraenkel L. Optimizing access to PrEP based on MSM preferences: results of a discrete choice experiment. AIDS Care. 2019;31(5):545–53.CrossRef
27.
Zurück zum Zitat Golub SA, Gamarel KE, Rendina HJ, Surace A, Lelutiu-Weinberger CL. From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. AIDS Patient Care STDs. 2013;27(4):248–54.CrossRef Golub SA, Gamarel KE, Rendina HJ, Surace A, Lelutiu-Weinberger CL. From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. AIDS Patient Care STDs. 2013;27(4):248–54.CrossRef
28.
Zurück zum Zitat Cohen SE, Kelley CF. Is the United States ready for event-driven human immunodeficiency virus preexposure prophylaxis? Clin Infect Dis. 2020;71(2):256–8.CrossRef Cohen SE, Kelley CF. Is the United States ready for event-driven human immunodeficiency virus preexposure prophylaxis? Clin Infect Dis. 2020;71(2):256–8.CrossRef
29.
Zurück zum Zitat Molina J-M, Ghosn J, Algarte-Genin M, Rojas-Castro D, Beniguel L, Pialoux G, et al. Incidence of HIV-infection with daily or on-demand PrEP with TDF/FTC in Paris area—update from the ANRS Prevenir Study. In: 10th IAS Conference on HIV Science: International AIDS Society. Hoboken: Wiley; 2019. Molina J-M, Ghosn J, Algarte-Genin M, Rojas-Castro D, Beniguel L, Pialoux G, et al. Incidence of HIV-infection with daily or on-demand PrEP with TDF/FTC in Paris area—update from the ANRS Prevenir Study. In: 10th IAS Conference on HIV Science: International AIDS Society. Hoboken: Wiley; 2019.
30.
Zurück zum Zitat World Health Organization. Technical brief: what’s the 2+ 1+ 1? Event-driven oral pre-exposure prophylaxis to prevent HIV for men who have sex with men: update to WHO’s recommendation on oral PrEP. Geneva: World Health Organization; 2019. World Health Organization. Technical brief: what’s the 2+ 1+ 1? Event-driven oral pre-exposure prophylaxis to prevent HIV for men who have sex with men: update to WHO’s recommendation on oral PrEP. Geneva: World Health Organization; 2019.
31.
Zurück zum Zitat Department of Health and Mental Hygiene. “On-Demand” dosing for PrEP: guidance for medical providers. New York City: Department of Health and Mental Hygiene; 2019. Department of Health and Mental Hygiene. “On-Demand” dosing for PrEP: guidance for medical providers. New York City: Department of Health and Mental Hygiene; 2019.
32.
Zurück zum Zitat Department of Health—Population Health Division; Important HIV prevention and treatment updates for San Francisco providers. San Francisco: Department of Health—Population Health Division; 2019. Department of Health—Population Health Division; Important HIV prevention and treatment updates for San Francisco providers. San Francisco: Department of Health—Population Health Division; 2019.
33.
Zurück zum Zitat Department of Health. PrEP 2-1-1: “On-Demand” pre-exposure prophylaxis (PrEP) for sexual intercourse. California: Department of Health; 2019. Department of Health. PrEP 2-1-1: “On-Demand” pre-exposure prophylaxis (PrEP) for sexual intercourse. California: Department of Health; 2019.
34.
Zurück zum Zitat Dimitrov D, Moore JR, Wood D, Mitchell KM, Li M, Hughes JP, et al. Predicted effectiveness of daily and nondaily preexposure prophylaxis for men who have sex with men based on sex and pill-taking patterns from the human immuno virus prevention trials network 067/ADAPT study. Clin Infect Dis. 2020;71(2):249–55.CrossRef Dimitrov D, Moore JR, Wood D, Mitchell KM, Li M, Hughes JP, et al. Predicted effectiveness of daily and nondaily preexposure prophylaxis for men who have sex with men based on sex and pill-taking patterns from the human immuno virus prevention trials network 067/ADAPT study. Clin Infect Dis. 2020;71(2):249–55.CrossRef
35.
Zurück zum Zitat Marks SJ, Merchant RC, Clark MA, Liu T, Rosenberger JG, Bauermeister J, et al. Potential healthcare insurance and provider barriers to pre-exposure prophylaxis utilization among young men who have sex with men. AIDS Patient Care STDs. 2017;31(11):470–8.CrossRef Marks SJ, Merchant RC, Clark MA, Liu T, Rosenberger JG, Bauermeister J, et al. Potential healthcare insurance and provider barriers to pre-exposure prophylaxis utilization among young men who have sex with men. AIDS Patient Care STDs. 2017;31(11):470–8.CrossRef
36.
Zurück zum Zitat Spiegelman D, Easy SAS. Calculations for risk or prevalence ratios and differences. Am J Epidemiol. 2005;162(3):199–200.CrossRef Spiegelman D, Easy SAS. Calculations for risk or prevalence ratios and differences. Am J Epidemiol. 2005;162(3):199–200.CrossRef
37.
Zurück zum Zitat SAS Institute Incorporated. SAS (Version 9.4). Cary: SAS Institute Incorporated; 2013. SAS Institute Incorporated. SAS (Version 9.4). Cary: SAS Institute Incorporated; 2013.
38.
Zurück zum Zitat Doblecki-Lewis S, Butts S, Botero V, Klose K, Cardenas G, Feaster D. A randomized study of passive versus active PrEP patient navigation for a heterogeneous population at risk for HIV in South Florida. J Int Assoc Provid AIDS Care (JIAPAC). 2019;18:232595821984884.CrossRef Doblecki-Lewis S, Butts S, Botero V, Klose K, Cardenas G, Feaster D. A randomized study of passive versus active PrEP patient navigation for a heterogeneous population at risk for HIV in South Florida. J Int Assoc Provid AIDS Care (JIAPAC). 2019;18:232595821984884.CrossRef
Metadaten
Titel
Predictors of Event-Driven Regimen Choice in Current PrEP Users and Sexual Behavior Characteristics of MSM Receiving Sexual Health Services in New York City
verfasst von
Pedro B. Carneiro
Christopher Rincon
Sarit Golub
Publikationsdatum
27.02.2021
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 8/2021
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-021-03203-1

Weitere Artikel der Ausgabe 8/2021

AIDS and Behavior 8/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.